In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business. In this episode, Megan Thomas is in conversation with Steve Ruston, CEO… Read More
DDW’s Diana Spencer reviews the latest research into fibromyalgia treatment and the new therapies currently in development. With no existing cure for fibromyalgia, a chronic pain syndrome, current treatments focus on managing the symptoms like pain, fatigue and poor sleep, with exercise being a key part of… Read More
Persica Pharmaceuticals has announced positive topline data from its Phase Ib Modic Trial for PP353, a drug candidate with the potential to offer patients an alternative to long-term opioid use for pain relief by targeting the cause of the pain rather than the symptoms. The trial is… Read More
University of Queensland (UQ) researchers have developed a new class of oral painkillers to suppress chronic abdominal pain that is based on the peptide hormone oxytocin. The team changed the chemical structure of oxytocin to make it gut-stable after earlier work revealed the hormone could treat… Read More
The US Food and Drug Administration (FDA) has approved Roxybond (oxycodone hydrochloride) 10mg for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. The approval makes Roxybond the first FDA-approved abuse-deterrent immediate release (IR) 10mg oxycodone formulation… Read More
The US Food and Drug Administration (FDA) has granted Fast Track designation to Tonix Pharmaceuticals’ Tonmya (cyclobenzaprine HCl sublingual tablets) for the management of fibromyalgia. Tonmya is a non-opioid, centrally-acting analgesic drug under development for treating fibromyalgia, which is a common chronic pain condition affecting mostly… Read More
German company Grünenthal has acquired US-based Valinor Pharma along with its product Movantik (naloxegol) for approximately $250 million. Movantik is indicated for the oral treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain. Gross sales from the drug in the United States (US)… Read More
DDW Editor Reece Armstrong speaks to Michael Krogh Jensen, Co-founder and CEO of Biomia, about developing plant-based medicines and what recent investment and support from the Bio Studio programme means for its pipeline. RA: How has being part of the Bio Studio programme helped you develop your pipeline?… Read More
A new compound reversed four types of chronic pain in animal studies, according to research led by New York University (NYU) College of Dentistry’s Pain Research Center. The small molecule, which binds to an inner region of a calcium channel to indirectly regulate it, outperformed gabapentin… Read More
Scientists from Boston University have published evidence that the atypical antidepressant tianeptine potentially provides rapid and lasting neuropathic pain relief with a low risk of addiction. The researchers from Boston University Chobanian & Avedisian School of Medicine in collaboration with the Icahn School of Medicine, Columbia… Read More
The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has approved a CBD/THC combination treatment under its Named Patient programme and other compassionate areas. Medlab’s NanaBis, to be used under NanaDol, a botanical version of NanaBis, has previously shown encouraging Phase I/II data for the treatment of… Read More
Three international life sciences start-ups have received investment from the BioInnovation Institute (BII). The three new ventures were chosen as part of the BII’s focus on developing scientific initiatives across the therapeutics and health tech space. The companies, Sevenless Therapeutics, VEIL.AI and Myopax, will receive… Read More
Virpax Pharmaceuticals has chosen Altasciences to conduct a first-in-human study of Epoladerm (diclofenac epolamine) for chronic pain associated with osteoarthritis of the knee. This treatment is supplied in a pre-filled device for administration as a topical spray film. The study The study will be conducted in the second quarter of 2022… Read More
1910 Genetics has been awarded an approximate $550,000 Phase I STTR grant by the National Institutes of Health (NIH). The grant, received from the National Institute of Neurological Disorders and Stroke (NINDS) as part of the Helping to End Addiction Long-term Initiative, or NIH HEAL Initiative, supports… Read More
New research conducted by the University of Oxford, Baylor College of Medicine, the University of Wisconsin-Madison and Bayer AG, offers new insight into how to treat endometriosis, a painful, chronic condition in which tissue from the uterus inappropriately grows outside the uterus. Current treatments are limited and include surgery and… Read More
An international study led by McMaster University scientists and published in The British Medical Journal show a minority of people living with chronic pain who try medical cannabis may experience important relief and the risk of side effects is typically small. Data from 32 randomised controlled trials showed that… Read More
